Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder

cancer.

Authors: Reham Abdel-Wahab, MD, PhD1,9,10, Timothy Yap, MD, PhD2, Russell Madison, PhD4,

Shubham Pant, MD^{1,2}, Matthew Cooke, PhD⁴, Kai Wang, MD, PhD^{4,5,7}, Zhao Haitao, MD, PhD⁸, Tanios

Bekaii-Saab, MD⁶, Elif Karatas, MD¹, Lawrence Kwong, PhD³, Funda Meric-Bernstam, MD², Mitesh

Borad, MD⁶, Milind Javle, MD^{1*}

Authors Affiliations:

¹Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center,

Houston, TX, USA

²Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX,

USA

³Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center,

Houston, TX, USA

⁴Foundation Medicine, Cambridge, MA, USA

⁵OrigiMed, Shanghai, China

⁶Mayo Clinic, Rochester, MN, USA

⁷Zhejiang University International Hospital, Hangzhou, China

⁸Peking Union Medical College, Beijing, China

⁹Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt

¹⁰Cholangiocarcinoma Foundation, Utah, USA

Correspondence:

Milind Javle, MD, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas

MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Telephone: 713-792-2828; Fax:

713-745-1163; E-mail: mjavle@mdanderson.org

Key Words: gallbladder cancer; DNA repair genetic aberrations; targeted therapy

Word count: 3080

Number of Figures: 5 figures and 9 supplemental figures

Number of Tables: 2 tables and 1 supplemental table



